Management of Non-Localized Cervical Cancers at the Dakar Cancer Institute: A Study of 407 Cases

Objectives: Non-localized cervical cancers include all malignant cervical tumors classified between IB3 and IV according to the FIGO classification. The objective of our study was to describe the management of these cancers at the Dakar Cancer Institute. Materials and Methods: This was a retrospective study conducted over a four-year period, including all histologically diagnosed cases of non-localized cervical cancer. Results: During the study period, 407 patient records were analyzed. The mean age of patients was 53.5 ± 11.2 years. Among them, 331 (81.3%) were married, and 373 (91.6%) were grand multiparas. Metrorrhagia was present in 342 patients (83.9%). FIGO stage IIb was the most frequent (98 cases, 24.1%), and the predominant histological type was squamous cell carcinoma (383 cases, 94.1%). All patients received neoadjuvant chemotherapy, primarily with a carboplatin-taxol regimen (396 cases, 97.3%), with a complete response observed in 225 patients (55.3%). Adjuvant treatment consisted of exclusive radiotherapy for 245 patients (60.2%), with an estimated three-year survival rate of 30%. Prognostic factors identified in multivariate analysis included parametrial involvement (p = 0.005), chemotherapy regularity (p = 0.013), and response to chemotherapy (p Conclusion: The management of non-localized cervical cancers primarily relies on radio-chemotherapy. In our context, the use of neoadjuvant chemotherapy remains essential.